Related Experiment Video
Updated: Apr 30, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell
Robert D Simari1, Carl J Pepine, Jay H Traverse
1From Mayo Clinic, Rochester, MN (R.D.S., D.B.S.); University of Florida School of Medicine, Gainesville (C.J.P., R.D.A.); Minneapolis Heart Institute at Abbott Northwestern Hospital, University of Minnesota School of Medicine (J.H.T.); Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); University of Louisville School of Medicine, KY (R.B.); The University of Texas MD Anderson Cancer Center, Houston (E.Y.); University of Miami Miller School of Medicine, FL (J.M.H., I.H.S.); Florida Hospital Tampa Pepin Heart Institute (C.L.); University of Texas Health Science Center School of Public Health, Houston (S.L.S., L.A.M.); Texas Heart Institute, Houston (D.A.T.); and National Heart, Lung, and Blood Institute, Bethesda, MD (R.F.E.).
Insights
Bone marrow mononuclear cells show promise for treating acute myocardial infarction. Further research is needed to optimize cell therapy strategies for heart attack recovery.
Area of Science:
- Cardiology
- Regenerative Medicine
- Cell Therapy
Background:
- Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide.
- Current treatments aim to restore blood flow but often result in significant myocardial damage.
- Cell-based therapies are being explored to enhance cardiac repair post-AMI.
Purpose of the Study:
- To evaluate the role of bone marrow mononuclear cells (BM-MNCs) in treating acute myocardial infarction.
- To retrospectively analyze the strengths and limitations of three contemporary clinical trials.
- To provide insights into future directions for cell therapy in AMI.
Main Methods:
- Retrospective review of three contemporaneous clinical trials involving BM-MNCs for AMI.
- Critical examination of trial design features.
- Analysis of combined data from the selected trials.
Main Results:
- Identified critical design features influencing the efficacy of BM-MNC therapy.
- Highlighted variability in trial outcomes and methodologies.
- Synthesized findings to inform future research protocols.
Conclusions:
- Bone marrow mononuclear cells hold therapeutic potential for acute myocardial infarction.
- Standardization of trial design and methodology is crucial for advancing cell therapy.
- Further investigation is warranted to optimize cell delivery and patient selection for AMI treatment.
Abstract:
To understand the role of bone marrow mononuclear cells in the treatment of acute myocardial infarction, this overview offers a retrospective examination of strengths and limitations of 3 contemporaneous trials with attention to critical design features and provides an analysis of the combined data set and implications for future directions in cell therapy for acute myocardial infarction.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Myocarditis III: Medical Management
Acute Coronary Syndrome IV: Interprofessional Care
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Myocarditis I: Introduction

